Hematide entered into phase 3 clinical program to treat anemia in chronic renal failure patients in Japan
Takeda Pharmaceutical Company Limited announced that the investigational compound, Hematide™, of which Takeda and Affymax Inc contracted the global license agreement, for the treatment of anemia in chronic renal failure has entered into phase 3 clinical program in Japan.
Hematide™, a synthetic, peptide-based erythropoiesis-stimulating agent (ESA), is designed to act on the erythropoietin receptors and stimulate the production of red blood cells by dosing once every four weeks.
Takeda and Affymax have been conducting phase 3 program in the US and EU. Follow-up of patients in the phase 3 program was completed in January 2010 and top-line study results are expected to be reported in the 1Q of FY 2010. An NDA submission in the U.S. is expected later in 2010.
Other news from the department research and development
